tickrz reports
  
tickrz rank
D
C R Bard Inc (BCR)
Healthcare | Medical Instruments & Supplies
CEO: Tim M. Ring
Employees: 14900
crbard.com
FACTOR RANKINGSFACTOR SCREENER 
Pure Value Rank456Dividend Rank121
Moat Rank234Financial Strength Rank119
Growth Rank184Momentum Rank197
DIVIDEND ANALYSIS
Dividend Yield0.34%
Payout Ratio12.79%
3 yr Dividend Growth6.84%
VALUATION RATIOS
P/E Ratio37.89x
P/B Ratio13.45x
P/S Ratio5.95x
EV/EBITDA Ratio23.35x
FINANCIAL STRENGTH
Piotroski F-Score8
Debt-to-Equity105%
Interest Coverage13.39x
MOAT
ROE37.89%
ROIC35.07%
Net Margin14.24%
GROWTH
5 yr EPS Growth13.76%
5 yr SPS Growth5.1%
5 yr BPS Growth1.74%
C R Bard Inc's strong Dividend Rank may warrant a closer look for investors seeking dividend paying stocks
 tickrz summary
C R Bard Inc receives a D ranking in our proprietary ranking system that combines valuation, moat, operational performance, and financial strength. View the Top 50 tickrz ranked stocks here.
 value
 pure value ranking Warren Buffett ranking
Valuation is the most heavily weighted component in our tickrz ranking methodology. Numerous academic and practitioner studies have found that a value approach outperforms the market over the long-run. C R Bard Inc's valuation score is comprised of a P/E ratio of 37.9x, a P/B ratio of 13.5x, a P/S ratio of 6x, and an EV/EBITDA ratio of 23.4x. C R Bard Inc ranks 456 out of the S&P 500 constituents on valuation--a relatively weak score.C R Bard Inc ranks 275 out of the S&P 500 constituents in our multi-factor Warren Buffett ranking methodology. This is a average score, meaning it ranks in the middle of the pack on valuation, moat, volatility, and financial strength factors. If you're looking for undervalued stocks with high moats and strong competitive advantages, C R Bard Inc is probably not for you.

 quality
 moat financial strength
To calculate a company's Moat Score, we look at its historical earnings growth, historical average return on equity, the volatility of its earnings stream, and also factor in the strength of its balance sheet. Our approach concludes the company's business moat is average. Our analysis of its moat reveals neither a durable moat or enduring competitive advantages.C R Bard Inc has a Piotroski F Score of 8 out of 9. The F Score examines changes in profitability, leverage, liquidity, and operating efficiency. Interest coverage of 13.39x, a debt/equity ratio of 105% and a Moat Rank of 234 translate to a strong Financial Strength score.


 momentum
Investment research has shown that stocks with strong performance over the last 6 to 12 months tend to perform better in the medium term than stocks with poor performance over the same period. In fact, the momentum factor is one of the strongest of all the investment factors. The company has seen its stock appreciate by 16.24% over the last 12 months. This performance is average compared to other stocks in the S&P 500, earning it a rank of 197. Based on its 12 month stock performance, C R Bard Inc will not appeal to momentum investors.

 yield
 value + yield
Shares currently yield 0.34%. Our dividend ranking approach looks at a company's dividend growth rate, payout ratio, business moat, and valuation. Based on our methodology, C R Bard Inc ranks 121 among the S&P 500 constituents. Investors looking for undervalued dividend stocks will want to closely investigate C R Bard Inc.

 growth
A company's growth metrics are less important than its valuation, moat, and financial strength. However, a check on growth can be a good way to avoid companies in secular decline. The company's growth in sales, earnings, and book value produce an average score. 13.8% 5 year annualized EPS growth, 5.1% 5 year annualized sales-per-share growth, and 5 year annualized book value-per-share growth of 1.7% combine to produce this average score.

C R Bard Inc (BCR)
Healthcare | Medical Instruments & Supplies
CEO: Tim M. Ring
Employees: 14900
crbard.com


tickrz rank
D

VALUATION RATIOS
P/E Ratio37.89x
P/B Ratio13.45x
P/S Ratio5.95x
EV/EBITDA Ratio23.35x
DIVIDEND ANALYSIS
Dividend Yield0.34%
Payout Ratio12.79%
3 yr Dividend Growth6.84%
FINANCIAL STRENGTH
Piotroski F-Score8
Debt-to-Equity105%
Interest Coverage13.39x
MOAT
ROE37.89%
ROIC35.07%
Net Margin14.24%
GROWTH
5 yr EPS Growth13.76%
5 yr SPS Growth5.1%
5 yr BPS Growth1.74%

TICKRZ RANK
C R Bard Inc receives a D ranking in our proprietary ranking system that combines valuation, moat, operational performance, and financial strength. View the Top 50 tickrz ranked stocks here.

PURE VALUE
Valuation is the most heavily weighted component in our tickrz ranking methodology. Numerous academic and practitioner studies have found that a value approach outperforms the market over the long-run. C R Bard Inc's valuation score is comprised of a P/E ratio of 37.9x, a P/B ratio of 13.5x, a P/S ratio of 6x, and an EV/EBITDA ratio of 23.4x. C R Bard Inc ranks 456 out of the S&P 500 constituents on valuation--a relatively weak score.

WARREN BUFFETT RANKING
C R Bard Inc ranks 275 out of the S&P 500 constituents in our multi-factor Warren Buffett ranking methodology. This is a average score, meaning it ranks in the middle of the pack on valuation, moat, volatility, and financial strength factors. If you're looking for undervalued stocks with high moats and strong competitive advantages, C R Bard Inc is probably not for you.

MOAT
To calculate a company's Moat Score, we look at its historical earnings growth, historical average return on equity, the volatility of its earnings stream, and also factor in the strength of its balance sheet. Our approach concludes the company's business moat is average. Our analysis of its moat reveals neither a durable moat or enduring competitive advantages.

FINANCIAL STRENGTH
C R Bard Inc has a Piotroski F Score of 8 out of 9. The F Score examines changes in profitability, leverage, liquidity, and operating efficiency. Interest coverage of 13.39x, a debt/equity ratio of 105% and a Moat Rank of 234 translate to a strong Financial Strength score.

MOMENTUM
Investment research has shown that stocks with strong performance over the last 6 to 12 months tend to perform better in the medium term than stocks with poor performance over the same period. In fact, the momentum factor is one of the strongest of all the investment factors. The company has seen its stock appreciate by 16.24% over the last 12 months. This performance is average compared to other stocks in the S&P 500, earning it a rank of 197. Based on its 12 month stock performance, C R Bard Inc will not appeal to momentum investors.

VALUE + YIELD
Shares currently yield 0.34%. Our dividend ranking approach looks at a company's dividend growth rate, payout ratio, business moat, and valuation. Based on our methodology, C R Bard Inc ranks 121 among the S&P 500 constituents. Investors looking for undervalued dividend stocks will want to closely investigate C R Bard Inc.

GROWTH
A company's growth metrics are less important than its valuation, moat, and financial strength. However, a check on growth can be a good way to avoid companies in secular decline. The company's growth in sales, earnings, and book value produce an average score. 13.8% 5 year annualized EPS growth, 5.1% 5 year annualized sales-per-share growth, and 5 year annualized book value-per-share growth of 1.7% combine to produce this average score.